Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Featured Content from MarketBeat 3 Up-and-Coming Stocks Showing Huge Momentum in Late 2025Written by Chris Markoch. Published 12/2/2025. Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have also been several up-and-coming stocks in other sectors that posted impressive gains this year. The three stocks in this article are still small-cap names; the largest market cap is just over $4 billion. However, they've made strong moves and reinforce the idea that time in the market is often better than trying to time the market. That said, if investors could see the future with absolute clarity, investing would be easy. Unfortunately, the future is rarely clear, and a bullish outcome is not guaranteed. Still, the charts speak for themselves: investors who bought these stocks and had the patience to hold through rough patches are reaping the benefits today. Better yet, the stocks may not be done moving higher. Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst World's Top Investors Preparing for Trump's Secret Plan…?
It's been on his agenda since 2016 - and if you understand what's happening, it could represent a once-a-generation financial opportunity. Click here for the full story before it's too late. Key Points - These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
- Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
- Analysts remain bullish, with price targets indicating potential double-digit to triple-digit returns from current levels.
Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company that recently delivered positive data for its first-in-class PI3K/mTOR inhibitor targeting HR+/HER2- metastatic breast cancer. The company's pivotal Phase 3 VIKTORIA trial is underway, and many believe it could receive U.S. Food & Drug Administration (FDA) approval in 2026. Investors have been front-running those expectations, pushing CELC stock up more than 660%, with nearly all of those gains occurring since the end of July. At $99.30 as of this writing, the stock is within about 3% of its consensus price target. However, Jefferies raised its price target on the stock to $134 from $108 on December 2. The biggest risk investors face is the financial cost of commercialization. In its most recent earnings report, Celcuity showed a reinforced balance sheet with $455 million in cash, cash equivalents, and short-term investments — up about 72% year over year — and management believes that will be sufficient until commercialization begins. Fintech Disruptor Turning Revenue Growth Into Real Momentum When traditional banks offer less to many consumers, it's easy to make the case for Dave Inc. (NASDAQ: DAVE), a Los Angeles-based fintech company known for its Dave app. The Dave app provides affordable, transparent financial tools that help users — many of whom live paycheck to paycheck — avoid overdraft fees, budget more effectively, and access short-term cash when needed. The company recently reported a 64% year-over-year increase in revenue and an 85% beat on adjusted earnings per share (EPS). DAVE stock is up 120% in 2025, and analysts see more upside. As of this writing the stock is trading at $208.24, while the consensus price target sits at $304.25 — an implied upside of more than 46%. Some investors may worry about the company's forward price-to-earnings (P/E) ratio of roughly 119x. However, analysts forecast earnings growth of over 117% in the next 12 months, and that pace of growth would help justify a higher valuation. Resale Retail Winner Riding a Massive Consumer Shift It's been another rough year for consumer staples stocks, but ThredUp Inc. (NASDAQ: TDUP) has been a notable exception. TDUP stock is up more than 430% in 2025, despite a sell-off of over 29% in the three months ending December 1. The company operates an online consignment marketplace, positioning it well as many consumer budgets remain stretched. The thrift and resale market was a $49 billion industry in 2024 and is expected to grow to $74 billion by 2029. TDUP is the smallest of the three stocks on this list, and short interest above 17% indicates active trading. Still, the company's Q3 earnings report showed strong year-over-year revenue growth and, perhaps more importantly, a record for new buyer acquisition along with a 37% year-over-year increase in orders. This could be a shorter-term trade for some investors. However, the younger generation that forms ThredUp's core market is likely to remain budget-conscious for some time, which helps explain why analysts assign TDUP a consensus price target of $12.50 — roughly a 68% gain from its closing price on December 1.
| 
